Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Orexigen Therapeutic (OREX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 28,590
  • Shares Outstanding, K 14,590
  • Annual Sales, $ 24,460 K
  • Annual Income, $ -68,690 K
  • 36-Month Beta 3.02
  • Price/Sales 1.09
  • Price/Book 0.36

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.75 +8.57%
on 12/01/16
2.65 -28.30%
on 11/14/16
-0.51 (-21.16%)
since 11/02/16
3-Month
1.75 +8.57%
on 12/01/16
3.96 -52.02%
on 09/06/16
-1.96 (-50.78%)
since 09/02/16
52-Week
1.75 +8.57%
on 12/01/16
24.00 -92.08%
on 12/03/15
-22.00 (-92.05%)
since 12/02/15

Most Recent Stories

More News
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave® (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Valeant Pharmaceuticals International, Inc. (Valeant), through a wholly owned subsidiary, will commercialize Contrave® (naltrexone HCl /...

Orexigen (OREX) Posts Narrower-than-Expected Loss in Q3

Orexigen (OREX) reported a loss of $1.01 per share in the third quarter of 2016, narrower than the Zacks Consensus Estimate of $2.13.

Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the third quarter ended September 30, 2016.

Orexigen Therapeutics to Present at 25th Annual Credit Suisse Healthcare Conference

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a corporate overview at the 25th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona. The presentation...

Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2016 Financial Results on November 3, 2016

Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce third quarter 2016 corporate and financial results on Thursday, November 3rd after the market closes. Following the announcement, Orexigen will...

Orexigen Therapeutics to Speak at the Rodman & Renshaw 18th Annual Global Investment Conference

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Rodman & Renshaw 18th Annual Global Investment Conference. The presentation is scheduled...

Orexigen Stock Up on Commercialization Deal for Contrave

Orexigen (OREX) announced that it has entered into a commercialization and distributorship agreement with Valeant Canada for Contrave in Canada.

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release)

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Valeant Canada, a subsidiary of Valeant Pharmaceuticals International, Inc., or its affiliates, will commercialize Contrave® (naltrexone...

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release)

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Valeant Canada, a subsidiary of Valeant Pharmaceuticals International, Inc., or its affiliates, will commercialize Contrave® (naltrexone...

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release)

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Valeant Canada, a subsidiary of Valeant Pharmaceuticals International, Inc., or its affiliates, will commercialize Contrave® (naltrexone...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III...

See More

Support & Resistance

2nd Resistance Point 2.09
1st Resistance Point 1.99
Last Price 1.90
1st Support Level 1.80
2nd Support Level 1.71

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.